Please provide your email address to receive an email when new articles are posted on . GlaxoSmithKline and Innoviva’s triple-combination therapy of fluticasone furoate, umeclidinium and vilanterol ...
London, UK, Thursday 23 March 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress ...
Also, the study showed a statistically significant and clinically meaningful reduction in the annual rate of moderate/severe exacerbations with FF/UMEC/VI compared to Symbicort Turbohaler, with closed ...
(Reuters) -AstraZeneca breached the UK pharmaceutical industry's code of practice after a website claim incorrectly stated that all newly diagnosed asthma patients aged 12 and above should receive its ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Symbicort Turbuhaler contains two active ingredients in one inhaler: ...
AstraZeneca’s (AZ’s) Symbicort (budesonide/formoterol) Turbohaler 200/6 has been approved in the UK as the first and only combination reliever therapy for adults ...
LONDON, Oct 18 (Reuters) - AstraZeneca Plc lost a key European patent on its two-in-one asthma drug Symbicort on Thursday but the drugmaker said it did not expect the move to have an immediate impact ...
GlaxoSmithKline plc and Innoviva, Inc. announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback